In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy (UpFrontPSMA)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04343885 |
Recruitment Status :
Recruiting
First Posted : April 13, 2020
Last Update Posted : November 7, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Metastatic Hormone Naive Prostate Cancer | Drug: 177Lu-PSMA-617 Drug: Docetaxel | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 140 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | UpFrontPSMA : A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel Versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer |
Actual Study Start Date : | April 21, 2020 |
Estimated Primary Completion Date : | April 2024 |
Estimated Study Completion Date : | April 2024 |

Arm | Intervention/treatment |
---|---|
Experimental: 177Lu-PSMA+ Docetaxel
7.5 GBq (± 10%) 177Lu-PSMA every 6 weeks x 2 cycles. Docetaxel 75 mg/m2 commencing 6 weeks later, every 3 weeks x 6 cycles
|
Drug: 177Lu-PSMA-617
Patients will be given 7.5GBq of 177Lu-PSMA every 6 weeks for 2 cycles.
Other Name: 177Lu-PSMA-617 also referred to as 177Lu-PSMA Drug: Docetaxel Docetaxel 75 mg/m2 given every 3 weeks for 6 cycles
Other Name: Taxotere (trade name) |
Docetaxel (Control)
Docetaxel 75 mg/m2 every 3 weeks x 6 cycles
|
Drug: Docetaxel
Docetaxel 75 mg/m2 given every 3 weeks for 6 cycles
Other Name: Taxotere (trade name) |
- Undetectable prostate specific antigen (PSA) rate at 12 months after commencement of protocol therapy [ Time Frame: Upto 32 months assuming 18 months to complete recruitment, a maximum of 1.6 months from consent to commencement of treatment for last patient and then 12 months from commencement of treatment for last patient. ]Undetectable PSA is defined as PSA ≤ 0.2ng/ml at 12 months after protocol treatment commencement. Patients who experience unequivocal radiographic (by conventional imaging modality) and/or clinical disease progression within 12 months of initiating protocol treatment will be considered as not having undetectable PSA at 12 months.
- Safety of 177Lu-PSMA followed by docetaxel compared to docetaxel alone [ Time Frame: Through completion of treatment, maximum 26 months. ]The type, grade and relationship to treatment of adverse events (AE) will be assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v 5.0
- Time to development of castration resistance between treatment Arms [ Time Frame: Through study completion, up until 2 years after the last patient commences treatment. ]Castration resistance is defined as rising PSA and/or radiographic progression despite castrate levels of testosterone (≤ 50ng/dL or ≤ 1.73nmol/L).To be measured from the date of randomisation to the date of first evidence of castration resistance.
- PSA-progression free survival (PSA-PFS) between treatment Arms [ Time Frame: Through study completion, up until 2 years after the last patient commences treatment. ]PSA progression is defined as a rise in PSA by more than 25% AND more than 2ng/mL above the nadir (lowest PSA point). This needs to be confirmed by a repeat PSA performed at least 3 weeks later. Early rises in PSA prior to 12 weeks will be disregarded in determining PSA progression. To be measured from the date of randomisation to the first date of evidence of PSA progression or date of death due to any cause.
- Radiographic-PFS (rPFS) between treatment Arms [ Time Frame: Through study completion, up until 2 years after the last patient commences treatment. ]Radiographic progression will be assessed by the investigator per RECIST1.1 for soft tissue and PCWG3 for bone lesions. To be measured from randomisation to the first date of documented radiographic progression using conventional imaging or death due to any cause, whichever occurs first.
- Early PSMA PET response between treatment Arms [ Time Frame: Through completion of 3 months after treatment commencement for last patient, maximum 23 months. ]PSMA PET response assessed 3 months after treatment commencement defined by central imaging review of 68Ga-PSMA PET CT images.
- Describe and compare health-related QoL within 12 months of treatment commencement between treatment Arms [ Time Frame: Through completion of 12 months after treatment commencement of last patient, maximum 32 months. ]
QoL will be assessed using the Functional Assessment of Cancer Therapy for Prostate Cancer (FACT-P) questionnaire. The primary endpoint for QoL is the area under the curve (AUC) of the trial outcome index (TOI).
QoL will be assessed at baseline, 6 weeks, 3 months, 6 months, 9 months and 12 months and will be scored according to the respective manuals.
- Describe and compare pain within 12 months of treatment commencement between treatment Arms [ Time Frame: Through completion of 12 months after treatment commencement of last patient, maximum 32 months. ]
Pain will be assessed using the Brief Pain Inventory - Short Form (BPI-SF). The primary endpoint for pain is the area under the curve (AUC) of the worst pain in 24h.
Pain and QoL will be assessed at baseline, 6 weeks, 3 months, 6 months, 9 months and 12 months and will be scored according to the respective manuals.
- Overall survival (OS) between treatment Arms [ Time Frame: Through study completion, up until 2 years after the last patient commences treatment. ]OS is defined as the time from randomisation to the date of death due to any cause.
- Assess the correlation between PSMA and FDG PET/CT parameters and clinical outcomes [ Time Frame: Through study completion, up until 2 years after the last patient commences treatment. ]Prognostic and predictive value of PET-derived parameters including molecular tumour volume parameters (volume, SUVmax, SUVmean) and radiomics from PET, CT or bone scans using data-characterisation algorithms will be assessed.
- Identify biomarkers potentially associated with clinical outcomes [ Time Frame: Through study completion, up until 2 years after the last patient commences treatment. ]Prognostic and predictive biomarkers associated with treatment outcome and response will be assessed. This will include any of the following: i) circulating tumour DNA ± tumour tissue (DNA repair genes, tumour suppressor genes, androgen receptor); and ii) whole blood RNA (androgen receptor splice variants, TMPRSS2:ERG fusion).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Gender Based Eligibility: | Yes |
Gender Eligibility Description: | Men with a diagnosis of de novo high-volume mHNPC by PSMA-PET/CT criteria |
Accepts Healthy Volunteers: | No |
Inclusion Criteria for study registration:
- Patient has provided written informed consent
- Male aged 18 years or older at screening
- Prostate cancer diagnosed within 12 weeks of commencement of screening
- Histologically or cytologically confirmed adenocarcinoma of the prostate without significant neuroendocrine differentiation or small cell histology OR metastatic disease typical of prostate cancer (i.e. involving bone or pelvic lymph nodes or para-aortic lymph nodes) with a rising serum PSA
- Evidence of metastatic disease on CT and/or bone scan
- PSA > 10ng/ml prior to commencement of medical ADT or surgical orchidectomy
-
Adequate haematological, renal and hepatic functions as defined by:
- Absolute neutrophil count >1.5 x 109/L
- Platelet count >100 x 109/L
- Haemoglobin ≥ 90g/L (no red blood cell transfusion in 4 weeks prior to randomisation)
- Creatinine Clearance ≥ 40mL/min (Cockcroft-Gault formula)
- Total bilirubin < 1.5 x ULN (unless known or suspected Gilbert syndrome)
- Aspartate transaminase (AST) or alanine transaminase (ALT) ≤ 2.0 x ULN (or ≤ 5.0 x ULN in the presence of liver metastases)
- Have a performance status of 0-2 on the ECOG Performance Scale (see Appendix 1)
- Life expectancy greater than 6 months with treatment
- Assessed by a medical oncologist as suitable for treatment with docetaxel
- Patients must agree to use an adequate method of contraception
- Willing and able to comply with all study requirements, including all treatments and required assessments including follow-up
Exclusion Criteria for Registration:
-
Any prior pharmacotherapy, radiation therapy, or surgery for metastatic prostate cancer. The following exceptions are permitted:
- Up to 4 weeks of ADT with luteinising hormone releasing hormone agonists or antagonists or orchiectomy ± concurrent anti-androgens are permitted prior to commencement of screening. At investigator discretion, patients may start ADT at commencement of protocol therapy
- Up to one course of palliative radiation or surgical therapy to treat symptoms resulting from metastatic disease if it was administered at least 14 days prior to registration
- Symptomatic cord compression, or clinical or imaging findings concerning for impending cord compression
- Central nervous system metastases
- Patients with Sjogren's syndrome
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator
-
Prior diagnosis of another cancer that was:
- More than 3 years prior to current diagnosis with subsequent evidence of disease recurrence or clinical expectation of recurrence greater than 10%
- Within 3 years of current diagnosis with the exception of successfully treated basal cell or squamous cell skin carcinoma or adequately treated non-muscle invasive bladder cancer (Tis, Ta and low grade T1 tumours)
Inclusion Criteria for Randomisation:
- Significant PSMA avidity on 68Ga-PSMA PET/CT, defined after central review as a minimum uptake of SUVmax 15 at a site of disease
- High-volume metastatic disease on 68Ga-PSMA PET/CT defined as visceral metastases or ≥ 4 bone metastases with ≥ 1 outside the vertebral column and pelvis (extra-axial skeleton)
- Patient continues to meet all the inclusion criteria for registration
Exclusion Criteria for Randomisation:
- Major FDG-PET discordance defined as presence of FDG positive disease with minimal PSMA expression in multiple sites (>5) or in more than 50% of total disease volume
- All the exclusion criteria for registration continue to not apply

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04343885
Contact: Arun Azad, MBBS PhD FRACP | +613 855 97165 | Arun.Azad@petermac.org | |
Contact: Michael Hofman, MBBS(Hons),FRACP,FAANMS,FICIS | +613 855 96914 | Michael.Hofman@petermac.org |
Australia, New South Wales | |
St Vincent's Hospital Sydney | Recruiting |
Sydney, New South Wales, Australia, 2010 | |
Contact: Anthony Joshua, BSc,MBBS,PhD,FRACP +612 8382 1111 Anthony.Joshua@svha.org.au | |
Contact: Louise Emmett, BHB,MBChB,FRACP, MD louise.emmett@svha.org.au | |
Australia, Queensland | |
Royal Brisbane and Women's Hospital | Recruiting |
Brisbane, Queensland, Australia, 4029 | |
Contact: Aneta Suder 0736468111 Aneta.Suder@health.qld.gov.au | |
Contact: David Pattison 0736468111 David.Pattison@health.qld.gov.au | |
Australia, South Australia | |
Royal Adelaide Hospital | Recruiting |
Adelaide, South Australia, Australia, 5000 | |
Contact: Hsiang Tan 08 707 40000 Hsiang.Tan@sa.gov.au | |
Contact: Ian Kirkwood 08 707 40000 Ian.Kirkwood@sa.gov.au | |
Australia, Victoria | |
Peter MacCallum Cancer Centre | Recruiting |
Melbourne, Victoria, Australia, 3000 | |
Contact: Arun Azad, MBBS PhD FRACP +613 855 97165 Arun.Azad@petermac.org | |
Contact: Michael Hofman, MBBS(Hons) FRACP FAANMS FICIS +613 8559 6914 Michael.Hofman@petermac.org | |
Austin Health | Recruiting |
Melbourne, Victoria, Australia, 3084 | |
Contact: Andrew Weickhardt 03 9496 3088 Andrew.Weickhardt@onjcri.org.au | |
Contact: Sze T Lee 03 9496 5007 szeting.lee@austin.org.au |
Principal Investigator: | Arun Azad, MBBS PhD FRACP | Peter MacCallum Cancer Centre, Australia | |
Principal Investigator: | Michael Hofman, MBBS(Hons),FRACP,FAANMS,FICIS | Peter MacCallum Cancer Centre, Australia |
Responsible Party: | Peter MacCallum Cancer Centre, Australia |
ClinicalTrials.gov Identifier: | NCT04343885 |
Other Study ID Numbers: |
19/195 |
First Posted: | April 13, 2020 Key Record Dates |
Last Update Posted: | November 7, 2022 |
Last Verified: | November 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Genital Diseases, Male Genital Diseases Urogenital Diseases Prostatic Diseases |
Male Urogenital Diseases Docetaxel 177Lu-PSMA-617 Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Radiopharmaceuticals |